Citius Pharmaceuticals (CTXR) Live Share Price, Invest From India

Citius Pharmaceuticals Stock Performance

as on October 3, 2026 at 6:59 am IST

Day's Low
Day's High
$0.53
Day's Price Range
$0.55
$0.53
0.39%
Downside
3.36%
Upside
52 Week's Low
52 Week's High
$0.47
52-Week Price Range
$2.19
$0.53
11.92%
Downside
311.58%
Upside

Citius Pharmaceuticals share price movements today

Previous Close: $0.54
Open: $0.53
Volume: 575.4K
Market Cap: $14.6M
Day's Low - High: $0.53 - $0.55
52 Week Low - High: $0.47 - $2.19

Citius Pharmaceuticals Historical Returns

1 Month Return: -6.78 %
3 Month Return: -5.99 %
1 Year Return: -59.38 %
3 Year Return: -96.76 %
5 Year Return: -98.94 %

Citius Pharmaceuticals Stock Fundamentals & Key Indicators

Check Citius Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$14.6M

EPS (TTM)

-2.11

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.25

Industry PE ratio

-2.26

PEG Ratio

-0.00

EBITDA

-57.2M

Revenue (TTM)

7.1M

Profit Margin

19.97%

Return On Equity TTM

-67.15%

Citius Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Citius Pharmaceuticals with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Citius Pharmaceuticals	Buy	$14.6M	-98.94%	-0.25	19.97%	0.00%
Revolution Medicines	StrongBuy	$44.0B	607.04%	-23.17	0.00%	0.00%
Moderna	Neutral	$76.9B	-44.61%	-24.13	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$132.5B	180.98%	30.19	86.04%	0.00%
Regeneron	Buy	$77.3B	28.74%	18.11	84.86%	0.49%

Stock Returns calculator for Citius Pharmaceuticals Stock including INR - Dollar returns

The Citius Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Citius Pharmaceuticals investment value today

Current value as on today

₹43,426

Returns

-₹56,574

(-56.57%)

Returns from Citius Pharmaceuticals Stock

-₹59,992 (-59.99%)

Dollar Impact

₹3,418 (+3.42%)

Analyst Recommendation on Citius Pharmaceuticals Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Citius Pharmaceuticals. Average target price of $4

Citius Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Citius Pharmaceuticals.

What analysts predicted

86.7%UPSIDE

Target Price

Current Price

$0.5321

Analyzed by

1 Analysts

High

Target

$4.00

Low

Citius Pharmaceuticals target price $4, a slight upside of 86.7% compared to current price of $0.5321. According to 1 analysts rating.

Indian Investors' Interest in Citius Pharmaceuticals Stock

Search interest for Citius Pharmaceuticals Stock has decreased by -74% in the last 30 days, reflecting a downward trend in search activity.

Time period: September 3, 2026 to October 3, 2026

Change:-74% versus previous 30 day period

Citius Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	3	1	1
Gross Profit	0	0	0	-	-	0	0	2	0	0
Operating Income	-10	-10	-11	-10	-11	-8	-8	-9	-32	-11
EBITDA	-10	-10	-10	-9	-11	-8	-8	-8	-30	-9
Interest Expense	-	-	-	-	-	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	1	1
Income Before Tax	-8	-10	-10	-10	-11	-8	-8	-9	-28	-12
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income	-8	-10	-10	-9	-10	-8	-7	-8	-21	-8
Net Profit Margin	0.00%	0.00%	-34.43%	0.00%	0.00%	0.00%	0.00%	65.45%	-22.90%	-48.09%

Citius Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Dec 2023	Sep 2024	Sep 2025
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	-	-	0	0
Operating Income	-9	-13	-15	-17	-23	-33	-36	-41	-38
EBITDA	-9	-13	-15	-17	-23	-33	-36	-38	-38
Interest Expense	0	0	0	0	0	-	-	-	0
Depreciation	0	0	0	0	0	0	0	0	0
Income Before Tax	-10	-12	-15	-17	-23	-33	-31	-38	-38
Income Tax Expense	-	-	0	-	-	0	0	0	1
Net Income	-10	-12	-15	-17	-23	-33	-32	-39	-37
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Citius Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-8	-10	-11	-10	-11	-9	-8	-9	-28	-8
Operating Cash Flow	-7	-8	-5	-4	-4	-5	-11	-13	-1	-8
Investing Cash Flow	-	-	-5	-	-	-	-5	-4	0	-2
Financing Cash Flow	-	13	-3	2	3	11	15	20	-1	23
Change in Cash	-7	5	-14	-2	-1	6	-1	3	-3	12

Citius Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Dec 2023	Sep 2024	Sep 2025
Net Income	-10	-12	-15	-17	-23	-33	-32	-39	-39
Operating Cash Flow	-7	-11	-12	-16	-24	-28	-29	-28	-26
Investing Cash Flow	0	-	-	0	-40	-	-	-5	-5
Financing Cash Flow	10	17	11	22	120	-	13	9	33
Change in Cash	2	5	-1	5	56	-28	-15	-23	1

Global Institutional Holdings in Citius Pharmaceuticals

Check out the Institutions with significant holdings in Citius Pharmaceuticals.

Funds	Holdings
TIAA-CREF Funds	1.77%
Vanguard	0.96%
VANGUARD INDEX FUNDS	0.61%
Fidelity Concord Street Trust	0.48%
Northern Funds	0.24%

See all

Insights on Citius Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 82.9% return, outperforming this stock by 179.7%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 566.0% return, outperforming this stock by 625.4%
NEGATIVE IMPACT
Price Dip
In the last 3 years, CTXR stock has moved down by -96.8%

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Organisation	Citius Pharmaceuticals
Headquarters	11 Commerce Drive, Cranford, NJ, 07016, US
Industry	Biotechnology
CEO	Leonard L. Mazur

Key Management of Citius Pharmaceuticals

Name	Title
Mr. Leonard L. Mazur	Co-Founder, CEO, Chairman & Secretary
Dr. Alan Lader Ph.D.	Senior VP and Head of Clinical Operations & Quality Assurance
Ms. Ilanit Allen	Vice President of Investor Relations & Corporate Communications
Mr. Dhananjay G. Wadekar	Senior Vice President of Business Strategy
Mr. Kelly Creighton Ph.D.	Executive Vice President of Chemistry, Manufacturing & Controls
Mr. Nikolas Burlew	Executive Vice President of Quality Assurance
Mr. Myron Z. Holubiak	Co-Founder & Executive Vice Chairman
Dr. Myron S. Czuczman M.D.	Executive VP & Chief Medical Officer
Mr. Jaime Bartushak	Chief Business Officer & CFO
Mr. Gary F. Talarico	Executive Vice President of Operations

FAQs

What is Citius Pharmaceuticals share price today?

Citius Pharmaceuticals share price today is $0.53 as on October 3, 2026 at 1:29 am IST at the close of the market. Citius Pharmaceuticals share today touched a day high of $0.55 and a low of $0.53.

What is the 52 week high and 52 week low for Citius Pharmaceuticals share?

Citius Pharmaceuticals share touched a 52 week high of $2.19 on October 20, 2025 and a 52 week low of $0.47 on July 20, 2026. Citius Pharmaceuticals stock price today i.e. October 3, 2026 at 1:29 am IST is closed at $0.53,which is 75.70% down from its 52 week high and 13.53% up from its 52 week low.

What is Citius Pharmaceuticals's market capitalisation today?

Citius Pharmaceuticals market capitalisation is $0.00T as on October 3, 2026 at 1:29 am IST.

How to invest in Citius Pharmaceuticals Stock (CTXR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Citius Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Citius Pharmaceuticals Stock (CTXR) from India?

Indian investors can start investing in Citius Pharmaceuticals (CTXR) shares with as little as ₹96.300003051758 or $1 (as of October 3, 2026 at 4:44 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Citius Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on October 3, 2026 at 4:44 am IST). Based on Citius Pharmaceuticals share’s latest price of $0.53 as on October 3, 2026 at 1:29 am IST, you will get 18.7935 shares of Citius Pharmaceuticals. Learn more about fractional shares .

What are the returns that Citius Pharmaceuticals has given to Indian investors in the last 5 years?

Citius Pharmaceuticals stock has given -98.94% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?